Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation

J Psychiatr Pract. 2016 Nov;22(6):459-462. doi: 10.1097/PRA.0000000000000185.

Abstract

A major medical problem for patients undergoing electroconvulsive therapy (ECT) is the occurrence of postictal agitation (PIA). This phenomenon is associated with confusion and disorientation that can have severe clinical implications for the safety of the patient and health care professionals. Many different pharmacological strategies have been used to prevent PIA. We present data on 40 patients who suffered from PIA after a course of ECT and evaluate the prophylactic use of orally disintegrating olanzapine in the prevention of PIA in subsequent ECT treatments.

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / pharmacology*
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / pharmacology*
  • Bipolar Disorder / therapy
  • Depressive Disorder, Major / therapy
  • Electroconvulsive Therapy / adverse effects
  • Electroconvulsive Therapy / methods*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Olanzapine
  • Psychomotor Agitation / etiology
  • Psychomotor Agitation / prevention & control*
  • Psychotic Disorders / therapy
  • Treatment Outcome
  • Young Adult

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Olanzapine